IN8BIO (INAB) is a clinical-stage biopharmaceutical company focused on therapies for the treatment of cancers. William Ho, President, CEO, and Co-Founder of IN8BIO, discusses the company and how IN8BIO went public via IPO on July 30th. He also talks about how IN8BIO develops gamma-delta T-cell therapies for the treatment of cancer. Tune in to find out more.
14 Oct 2021
The Watch List
28 Apr 2022
The Watch List
20 Apr 2022
Next Gen Investing
27 Jun 2022
Trading 360
18 Apr 2022
Market On Close
05 Apr 2022
The Watch List
28 Mar 2022